Skip to content

Discoveries to Change Lives.

The worrying and increasing development of bacterial
resistance has led to the search of alternative substances
to antibiotics. One of them is the application of phage-encoded
lytic proteins, known as enzybiotics, on which our company is focused.

Telum Therapeutics SL is a global drug discovery biotechnology
company specializing in the use of Engineered Phage Lytic
Proteins as new antimicrobial products.

Numerous studies place the bacteriophages and, specially, their lytic enzymes, as one of the most promising alternatives to the traditional
antibiotics. For this reason, Telum Therapeutics is creating a broad bacteria and phage collection from anthropogenic and cave explorations to obtain new bacteriophages and lytic enzymes with potential antibacterial therapeutic purposes.

Telum’s mission in the field of antibiotic drug development is to give hope to patients suffering with drug resistant infections by developing new antimicrobial agents.

APEXp® under Trade secret protection

Advanced Phage Enzybiotics from exploration platform

01
Sample collection
Sample Collection
02
Metagenome sequencing & lytic enzyme identification
Metagenome sequencing and lytic enzyme identification
03
Phage lytic protein modules
Phage lytic protein modules
04
TT Cloning & Jumbling Technology
TT Cloning and Jumbling Technology
05
Protein Engineering
Protein Engineering
06
Screening under Relevant conditions
Screening under Relevant conditions
07
Secondary Modifications
Secondary Modifications
08
Select Leading Candidates
Select Leading Candidates

APExTM

Advance Phage Enzybiotics from
exploration platform.

01
Sample collection
02
Metagenome sequencing & lytic enzyme identification
03
Phage lytic protein modules
04
TT Cloning & Jumbling Technology
05
Protein Engineering
06
Screening under Relevant conditions
07
Secondary Modifications
08
Select Leading Candidates

Telum Therapeutics Development Pipeline

Within our pipeline we have specific programs to treat serious multidrug-resistant Gram-negative infections caused by Enterobacteriaceae, Acinetobacter baumannii and Pseudomonas aeruginosa

Program / Product
Pathogen
Discovery
Preclinical
Patent

Ongoing

Future

P001/TT206 (GN EPLE)
Enterobacteriaceae (carbapenem-resistant, 3rd generation cephalosporin- resistant),Pseudomonas aeruginosa Acinetobacter baumannii, Klebsiella spp.
Infections caused by Gram-negative organisms, including cUTI, bacteremia, respiratory infections, etc.
PCT/EP2021/056264
P002 (GN EPLE)
Pseudomonas aeruginosa
Cystic fribrosis
P003 (GN EPLE)
Staphylococcus aureus MRSA
P004 (GP EPLE)
Broad spectrum; ESKAPE
P005 (GN&GP EPLE)
Vancomycin-resistant Enterococci
Program / Product
P001/TT206 (GN EPLE)
Pathogen
Enterobacteriaceae (carbapenem-resistant, 3rd generation cephalosporin-resistant),Pseudomonas aeruginosa Acinetobacter baumannii, Klebsiella spp.
Discovery & Preclinical
Infections caused by Gram-negative organisms, including cUTI, bacteremia, respiratory infections, etc.
Patent
PCT/EP2021/056264
Program / Product
P002 (GN EPLE)
Pathogen
Pseudomonas aeruginosa
Discovery & Preclinical
Cystic fribrosis
Patent
Program / Product
P003 (GN EPLE)
Pathogen
Staphylococcus aureus MRSA
Discovery & Preclinical
Patent
Program / Product
P004 (GP EPLE)
Pathogen
Broad spectrum; ESKAPE
Discovery & Preclinical
Patent
Program / Product
P005 (GN&GP EPLE)
Pathogen
Vancomycin-resistant Enterococci
Discovery & Preclinical
Patent

Abbreviations: EPLE: Engineered Phage Lytic Enzyme; GN, Gram negative bacteria; GP, Gram positive bacteria; ESKAPE, Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter spp